The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Bulevirtide: First Approval
Drugs. 2020 Sep 14.doi: 10.1007/s40265-020-01400-1. Online ahead of print.
Connie Kang1, Yahiya Y Syed2
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. firstname.lastname@example.org.
2Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Bulevirtide (Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV.